Regulatory Briefs: Contact Lenses; Circ Panel; Wheelchair Reclassification
This article was originally published in The Gray Sheet
FDA has scheduled its ophthalmic panel to discuss expectations for contact lenses and accessories next month. Also, its circulatory devices panel will consider extracorporeal membrane oxygenation classification, and other devices. Finally, FDA has formally classified stair-climbing wheelchairs as class II with special controls.
You may also be interested in...
The Circulatory System Devices Panel supported class II, with special controls, reclassification proposals from FDA for extracorporeal membrane oxygenators; external cardiac compressors; and external pacemaker pulse generators and triple chamber pacing system analyzers. But the panel had some additional requests for further action by the agency.
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.